Free Submission Public Relations &
Deutsch English


Address the challenges of CNS orphan diseases and learn from real-life case studies with QCTR

Print article Print article
2014-02-19 18:15:53 - SMi’s CNS Orphan Diseases – the alternative route in CNS masterclass - hosted by QCTR will take place on the 8th April in London

Visiongain’s new study predicts that the overall market for medicines to treat and manage unusual Central Nervous System (CNS) disorders will expand from 2014 to 2024. The strength of this pharma segment stems from incentives in orphan drug development, including regulatory filing and first-mover advantages and protection. Also, despite small patient numbers, pharma companies can expect steady demand for a drug after approvals and commercial launches. Strong prospects exist.
(Source: visiongain, “World Market For Orphan CNS Drugs Will Exceed $2.5BN in 2018?' , 2014)

SMi's masterclass hosted by QCTR will look at the challenges and potential advantages of developing drugs in CNS orphan diseases, compared to larger CNS indications and also looks at the support that is available to drug developers in

orphan diseases. It will look at case studies of drug companies who have followed this route.

Key benefits to this masterclass are:
• This masterclass is essential attendance for anyone who wants to understand clinical trials in a rare CNS
• Gain timely insight into key trial design strategies
• Discover the benefits of orphan disease regulations
• Learn from real-life case studies of how companies have approached these challenges

For more information and full programme details please visit:

Contact Information:
SMi Geoup Ltd

2nd Floor South, Harling House
47-51 Great Suffolk Street
United Kingdom

Contact Person:
Dan Lee
Marketing Executive
Phone: +44 20 7827 6078
email: email


Daniel Lee
Phone: 02078276078

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News


Terms & Conditions | Privacy | About us | Contact